



Aducanumab –

single-dose vial intravenous injection

-an amyloid beta-directed antibody

FDA grants accelerated approval for ADUHELM™ (Biogen and Eisai announced the news on Jun 7, 2021) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease.



Therapy cost: Biogen set Aduhelm’s list price at \$4,312 per infusion for a patient of average weight, or \$56,000 per year—several times higher than experts had previously estimated.



The global Alzheimer's disease treatment market is expected to reaching more than \$5 billion in next 6-8 years.



Pipeline- Biogen/Eisai – details of clinical trials will be made public in late 2022 for BAN2410 (lecanemab), targeting beta-amyloid.

Competition from Clinical Trials:

Molecule	Company
Donanemab	Eli Lilly
Solanezumab (LY2062430)	Eli Lilly
Ponezumab	Pfizer
Crenezumab	Roche
Gantenerumab	Roche
Bapineuzumab (abandoned)	JANSSEN – Elan- Pfizer